Denise A. Yardley
About
Denise A. Yardley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Denise A. Yardley has authored 279 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 244 papers in Oncology, 148 papers in Pulmonary and Respiratory Medicine and 87 papers in Cancer Research. Recurrent topics in Denise A. Yardley's work include Cancer Treatment and Pharmacology (154 papers), HER2/EGFR in Cancer Research (117 papers) and Advanced Breast Cancer Therapies (113 papers). Denise A. Yardley is often cited by papers focused on Cancer Treatment and Pharmacology (154 papers), HER2/EGFR in Cancer Research (117 papers) and Advanced Breast Cancer Therapies (113 papers). Denise A. Yardley collaborates with scholars based in United States, United Kingdom and France. Denise A. Yardley's co-authors include Hope S. Rugo, Howard A. Burris, John D. Hainsworth, Adam Brufsky, F. Anthony Greco, Véronique Dièras, Joyce O’Shaughnessy, Alison Stopeck, Eric P. Winer and Ada Braun and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.
In The Last Decade
Denise A. Yardley
275 papers receiving 12.5k citations
Hit Papers
Peers
Denise A. Yardley
Mikhail Lichinitser Russia
Valentina Guarneri Italy
Antonio Llombart‐Cussac Spain
Tadeusz Pieńkowski Poland
Maciej Krzakowski Poland
Joan Albanell Spain
Lee S. Rosen United States
Nicholas J. Robert United States
Andrew Wardley United Kingdom
Aňa Lluch Spain
Citations per year, relative to Denise A. Yardley Denise A. Yardley (= 1×)
peers
Mikhail Lichinitser
Countries citing papers authored by Denise A. Yardley
Since
Specialization
Citations
This map shows the geographic impact of Denise A. Yardley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise A. Yardley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise A. Yardley more than expected).
Fields of papers citing papers by Denise A. Yardley
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Denise A. Yardley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise A. Yardley. The network helps show where Denise A. Yardley may publish in the future.
Co-authorship network of co-authors of Denise A. Yardley
This figure shows the co-authorship network connecting the top 25 collaborators of Denise A. Yardley. A scholar is included among the top collaborators of Denise A. Yardley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denise A. Yardley. Denise A. Yardley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Untch, Michael, Denise A. Yardley, S-A Im, et al.. (2024). 240P Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE. Annals of Oncology. 35. S313–S314.
2.
Prat, Aleix, Nadia Solovieff, Fabrice André, et al.. (2023). Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7. Clinical Cancer Research. 30(4). 793–802.
3.
Sella, Tal, Yue Zheng, Nabihah Tayob, et al.. (2022). Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). npj Breast Cancer. 8(1). 127–127.
4.
Burris, Howard A., Arlene Chan, Aditya Bardia, et al.. (2021). Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. British Journal of Cancer. 125(5). 679–686.
5.
Tolaney, Sara M., Solmaz Sahebjam, Émilie Le Rhun, et al.. (2020). A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. 26(20). 5310–5319.
6.
Rugo, Hope S., Véronique Dièras, Javier Cortés, et al.. (2020). Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1. Breast Cancer Research and Treatment. 184(1). 161–172.
7.
Cobleigh, Melody, Denise A. Yardley, Adam Brufsky, et al.. (2019). Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clinical Cancer Research. 26(5). 1105–1113.
8.
Yardley, Denise A., William H. Liggett, Mark Mainwaring, et al.. (2019). A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Clinical Breast Cancer. 20(2). 89–97.
9.
Yardley, Denise A.. (2019). MONALEESA Clinical Program: A Review of Ribociclib use in Different Clinical Settings. Future Oncology. 15(23). 2673–2686.
10.
Yardley, Denise A., Lowell L. Hart, Patrick J. Ward, et al.. (2018). Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study. Clinical Breast Cancer. 18(5). e781–e787.
11.
Hurvitz, Sara A., Joyce O’Shaughnessy, Ginny Mason, et al.. (2018). Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clinical Cancer Research. 25(8). 2433–2441.
12.
O’Shaughnessy, Joyce, Angela DeMichele, X. Cynthia, et al.. (2018). A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment. 170(3). 547–557.
13.
Schwartzberg, Lee S., Denise A. Yardley, Anthony Elias, et al.. (2017). A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. Clinical Cancer Research. 23(15). 4046–4054.
14.
Yardley, Denise A., et al.. (2016). Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Clinical Breast Cancer. 16(3). 180–187.
15.
Gradishar, William J., Denise A. Yardley, Rachel M. Layman, et al.. (2015). Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. Clinical Cancer Research. 22(2). 301–309.
16.
Yardley, Denise A., Robert Weaver, Michelle Melisko, et al.. (2015). EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer. Journal of Clinical Oncology. 33(14). 1609–1619.
17.
Kaufman, Peter A., Kenneth J. Bloom, Howard A. Burris, et al.. (2014). Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Cancer. 120(17). 2657–2664.
18.
Kaufman, Peter A., Adam Brufsky, Musa Mayer, et al.. (2012). Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Research and Treatment. 135(3). 875–883.
19.
Brufsky, Adam, Musa Mayer, Hope S. Rugo, et al.. (2011). Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clinical Cancer Research. 17(14). 4834–4843.
20.
Stopeck, Alison, Allan Lipton, Jean-Jacques Body, et al.. (2010). Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. Journal of Clinical Oncology. 28(35). 5132–5139.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mikhail Lichinitser Breakdown of academic impact, for papers by Valentina Guarneri Breakdown of academic impact, for papers by Antonio Llombart‐Cussac Breakdown of academic impact, for papers by Tadeusz Pieńkowski Breakdown of academic impact, for papers by Maciej Krzakowski Breakdown of academic impact, for papers by Joan Albanell Breakdown of academic impact, for papers by Lee S. Rosen Breakdown of academic impact, for papers by Nicholas J. Robert Breakdown of academic impact, for papers by Andrew Wardley Breakdown of academic impact, for papers by Aňa Lluch